We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Bacterial Biofilms Associated with Colon Cancer

By LabMedica International staff writers
Posted on 21 Dec 2014
An imaging technology reveals that bacterial biofilms are associated with colon cancer (CRC) and the discovery draws on a novel way to observe microbial community structure.

The technology called combinatorial imaging could potentially be used to clinically diagnose pre-cancerous and cancerous conditions in the ascending colon, the part nearest to the small intestine. More...
Cancerous tumors in the ascending colon are characterized by biofilms, which are dense clumps of bacterial cells encased in a self-produced matrix.

Scientists at Johns Hopkins Medical Institutions (Baltimore, MD, USA) working with colleagues at the Marine Biological Laboratory, (Woods Hole, MA, USA) collected for analysis excess colon tumor, adenomas and cancers, and paired normal tissues from patients undergoing surgery. Healthy control patients undergoing screening colonoscopy or colonoscopy for diagnostic workup were also enrolled.

Colon tissues were analyzed with up to 11 fluorescent in situ hybridization (FISH) probes for bacterial composition and biofilm bacterial density and depth; by scanning electron microscopy (SEM), fluorescence microscopy for interleukin 6 (IL-6), and E-cadherin, enzyme-linked immunosorbent assay (ELISA) for (IL-6), and immunohistochemistry for pStat3, Ki67. Extracted sample DNA was amplified and sequence to determine the V3–V5 region of 16S rDNA using the Roche 454 method (Roche diagnostics; Branford, CT, USA).

The team identified invasive polymicrobial bacterial biofilms or bacterial aggregates structures previously associated with nonmalignant intestinal pathology. They were nearly universally on right-sided tumors (13 of 15 CRCs, 4 of 4 adenomas), but on only 12% of left-sided tumors (2 of 15 CRCs, 0 of 2 adenomas). Patients with biofilm-positive tumors, whether cancers or adenomas, all had biofilms on their tumor-free mucosa far distant from their tumors. Bacterial biofilms were associated with diminished colonic epithelial cell E-cadherin and enhanced epithelial cell IL-6 and Stat3 activation, as well as increased crypt epithelial cell proliferation in normal colon mucosa.

Jessica L. Mark Welch, PhD, a coauthor of the study, said, “This is the first time that biofilms have been shown to be associated with colon cancer, to our knowledge. This suggests that either the tumor allows the biofilm to form, or the biofilm is helping to cause the tumor. The breaching of the mucus layer could allow bacteria to come into contact with the host epithelial cells, and that is one thing that could lead to cancer.” The study was published on December 8, 2014, in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).

Related Links:

Johns Hopkins Medical Institutions
Marine Biological Laboratory
Roche Diagnostics 




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.